03/08/2026
๐
Today is ๐๐จ๐ซ๐ฅ๐ ๐๐ฎ๐ง๐ ๐๐๐ง๐๐๐ซ ๐๐๐ฒ
Although lung cancer remains the leading cause of cancer deaths worldwide, the survival rate has increased over the past few years due to the rapidly evolving treatment landscape for Non-Small Cell Lung Cancer (NSCLC).
As therapies become more biomarker-driven, the need for fast, accurate biomarker testing is critical.
๐ก๐๐๐ฒ๐ฅ๐ฅ๐โข ๐๐๐ฅ๐ข๐ฏ๐๐ซ๐ฌ ๐ฆ๐จ๐ฅ๐๐๐ฎ๐ฅ๐๐ซ ๐๐ข๐จ๐ฆ๐๐ซ๐ค๐๐ซ ๐ซ๐๐ฌ๐ฎ๐ฅ๐ญ๐ฌ ๐ข๐ง ๐จ๐ง๐ฅ๐ฒ ๐ ๐ก๐จ๐ฎ๐ซ๐ฌ!
https://www.biocartis.com/en/idylla-for-lung-cancer?utm_source=facebook&utm_medium=social&utm_campaign=0108_idylla-for-lung-cancer
๐๐จ๐ ๐๐ญ๐ก๐๐ซ, ๐ฐ๐ ๐๐๐ง ๐ก๐๐ฅ๐ฉ ๐ฅ๐ฎ๐ง๐ ๐๐๐ง๐๐๐ซ ๐ฉ๐๐ญ๐ข๐๐ง๐ญ๐ฌ ๐ ๐๐ญ ๐๐๐ฌ๐ญ, ๐๐๐๐ฎ๐ซ๐๐ญ๐ ๐ซ๐๐ฌ๐ฎ๐ฅ๐ญ๐ฌ ๐ช
The content of this post is only applicable to Idyllaโข EGFR Mutation Test & Idyllaโข GeneFusion Panel which are CE-marked in Europe. Idyllaโข EGFR Mutation Assay & Idyllaโข GeneFusion Assay are for Research Use Only (RUO), not for use in diagnostic procedures, in the US.